Copyright
©The Author(s) 2024.
World J Gastrointest Pharmacol Ther. May 5, 2024; 15(2): 91591
Published online May 5, 2024. doi: 10.4292/wjgpt.v15.i2.91591
Published online May 5, 2024. doi: 10.4292/wjgpt.v15.i2.91591
Therapy | Treatment endpoints | ||||
Clinical response | Clinical remission | Normalisation CRP/ESR | Decrease of faecal calprotectin | Mucosal healing | |
Oral 5-aminosalicylates | 4 | 8 | 8 | 10 | 13 |
Oral steroids | 2 | 2 | 5 | 8 | 11 |
Locally acting steroids | 3 | 8 | 8 | 9 | 13 |
Thiopurines | 11 | 15 | 15 | 15 | 20 |
Adalimumab | 6 | 11 | 10 | 12 | 14 |
Infliximab | 5 | 10 | 9 | 11 | 13 |
Vedolizumab | 9 | 14 | 14 | 15 | 18 |
Tofacitinib | 6 | 11 | 9 | 11 | 14 |
- Citation: Mitrev N, Kariyawasam V. Treatment endpoints in ulcerative colitis: Does one size fit all? World J Gastrointest Pharmacol Ther 2024; 15(2): 91591
- URL: https://www.wjgnet.com/2150-5349/full/v15/i2/91591.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v15.i2.91591